Alliance Pharmaceutical Corp.

Other

University of Illinois

University of California

Biofield Corp.

Fluoromed Pharmaceutical, Inc.

David M Long, Jr

Raymond A Long

Mark L Faupel

Gerald L Wolf

Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.

Lipid dispersions and methods of use

Prophylaxis in the parenteral administration of particulate dispersions

A method and apparatus for measuring biopotentials at a test site on a human or animal subject and determining therefrom the existence or status of a condition at such test site. The efficacy of treatment of a condition is monitored by comparing values obtained from biopotentials taken before treatment with those obtained during or after treatment. For disease diagnosis or screening, values obtained from biopotential measurements taken during a test period are processed in a neural network which has been programmed to recognize potential value patterns indicative of a disease condition.

Method and apparatus for disease, injury and bodily condition screening

The present invention relates to a composition for increasing the vascular dwell-time of a particulate therapeutic or diagnostic agent in a mammal through the adjunct administration of an effective amount of the particulate therapeutic or diagnostic agent and an effective amount of a vascular dwell-time enhancing agent. Suitable therapeutic and diagnostic agents include those whose efficacy within the body is predicated on their ability to remain within or to be carried within the vascular compartment. Accordingly this method can be readily adapted for treating several diseases and disorders, including hypoxia, hypoxemia, anemia and cancer and for imaging selected regions of a mammal by various imaging techniques, including ultrasound imaging, X-ray imaging and MRI imaging.

Method of extending the vascular dwell-time of particulate therapeutic

A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.

Stable, highly concentrated fluoro carbon emulsions

The present invention relates to method for preventing or treating cachexia in a mammal based on the administration of a therapeutically effective amount of an anti-cachexia agent. Suitable agents include ADP-ribose-polymerase inhibitors, ADP-ribose-transferase inhibitors, NADase inhibitors, nicotinamide benzamide, theophylline, thymine and analogs thereof.

Method for preventing and treating cachexia

Disclosed are fluorocarbon emulsions comprising amino acids and substances related to amino acids, such as substituted amino acids or amphoteric groups of amino acid side chains, for example, the imidazolyl group of histidine. Emulsion formulations comprising imidazole and imidazole based drugs possess anti-inflammatory and antipyretic properties which counteract transient inflammatory responses which occur when these emulsions are administered in vivo. Lipid constituents of histidine-containing emulsions are protected against oxidation caused by free radical formation. Disclosed also are emulsion formulations buffered with amino acids comprising histidine, imidazole, and related compounds that have a buffering capacity sufficient to maintain the emulsion pH within a specified range under storage conditions and protect these emulsions from the endogenous production of acid. Disclosed also is a method of calculation which assists in the selection of an optimum buffer composition and concentration to preserve physiological compatibility and stability of the emulsions within selected pH limits.

Fluorocarbon emulsions containing amino acid based anti-inflamatory

Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.

Percutaneous lymphography using particulate fluorocarbon emulsions

Brominated perfluorocarbon emulsions for internal animal use for

Biocompatible fluorcarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen.

Biocompatible stable fluorocarbon emulsions for contrast enhancement and

Perfluorocarbon hydrides, either alone or in combination with other perfluorocarbon compounds, may be introduced into a non-vascular animal space as a contrast agent in magnetic resonance imaging (MRI), computed tomography (CT) or conventional x-ray procedures. In the image generated by these systems, the fluorocarbon introduced into the space is contrasted with the remaining body tissues or spaces to distinguish the fluorocarbon-occupied space from other tissues and spaces. Perfluoroctyl hydride vaporizes at body temperature, and its gas phase, which also provides in effective contrast to tissues, is disclosed in imaging areas of comparatively large void volume while using a lower fluorocarbon dose then than required for fluid fluorocarbon. Perfluorocarbon hydrides offer less radiodensity to x-ray imaging and less hydrogen density to MRI imaging, and are disclosed as diluents for perfluorocarbon bromides in applications where concentrated brominated compounds are found to cause imaging artifacts. Perfluorocarbon emulsions comprising a mixture of perfluorocarbon bromide and at least 0.1% perfluorocarbon hydride are disclosed for intravascular use as a contrast agent or for oxygen transport.

Magnetic resonance imaging with perfluorocarbon hydrides

An up to 125% fluorocarbon emulsion for use in or with animal bodies and organs thereof, maintains emulsion stability through normal sterilization procedures with selective osmotic and buffering agents, maintains the emulsion at within predetermined osmolarity levels and, when desired, free of excessive calcium precipitation, reduces in vivo and in vitro red blood cell injury, reduces adverse anemia effects, reduces viscosity and reduces the rate of oxidation, and tends to equilibrate its distribution in major body organs thereby reducing toxicity. The osmotic agents may buffer and may provide nutrient in the form of sugars. The osmotic and buffering agents can comprise, selectively, hexahydric alcohols, namely mannitol and sorbitol; certain sugars, namely glucose, mannose and fructose; along with buffering agents that will affect osmolarity including imidazole, tris(hydroxymethyl)aminomethane, sodium chloride, sodium bicarbonate, monobasic potassium phosphate, dibasic potassium phosphate, calcium chloride, magnesium sulfate, monobasic sodium phosphate, dibasic sodium phosphate or combinations of them. The emulsion may include tocopherol. A method of emulsifying the fluorocarbon includes forced flow impingement under pressure after mixing the fluorocarbon into the discontinuous phase. The fluorocarbon emulsion can be used to deliver drugs and medicines soluble in, or transportable by the emulsion.

Biocompatible, stable and concentrated fluorocarbon emulsions for

Perfluorocarbon hydrides, either alone or in combination with other perfluorocarbon compounds, may be introduced into a non-vascular animal space as a contrast agent in magnetic resonance imaging (MRI), computed tomography (CT) or conventional x-ray procedures. In the image generated by these systems, the fluorocarbon introduced into the space is contrasted with the remaining body tissues or spaces to distinguish the fluorocarbon-occupied space from other tissues and spaces. Perfluoroctyl hydride vaporizes at body temperature, and its gas phase, which also provides an effective contrast to tissues, is disclosed in imaging areas of comparatively large void volume while using a lower fluorocarbon dose then than required for fluid fluorocarbon. Perfluorocarbon hydrides offer less radiodensity to x-ray imaging and less hydrogen density to MRI imaging, and are disclosed as diluents for perfluorocarbon bromides in applications where concentrated brominated compounds are found to cause imaging artifacts. Perfluorocarbon emulsions comprising a mixture of perfluorocarbon bromide and at least 0.1% perfluorocarbon hydride are disclosed for intravascular use as a contrast agent or for oxygen transport.

Biocompatible fluorocarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen. A method of preparing biocompatible fluorocarbon emulsions includes preparing a mixture of an emulsifying agent, osmotic agent, buffering agent, aqueous phase and fluorocarbon, forcing the mixture under high pressure into a cavity, against a surface and around a lip to cause turbulence and possibly cavitation to form high fluorocarbon concentration emulsions that are stable through heat sterilization; and, even when oxygenated, maintain substantially stable partial pressures of oxygen and of carbon dioxide, and substantially stable pH. A method of oxygenating high fluorocarbon concentration emuslions includes placing a measured amount of the emulsion in a container and causing the emulsion to form a thin film around the inner surface of the container when the oxygen is injected. An alternative method of oxygenating the high fluorocarbon concentration emulsion includes a two container system where one container, permeable to the to be dissolved gas, is formed within the other, and the emulsion is injected in one container and the to be dissolved gas is injected into the other container.

Growing community of inventors

El Cajon, CA, United States of America

David M Long, Jr